These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 18678674)

  • 1. The anthrax vaccine adsorbed vaccine generates protective antigen (PA)-Specific CD4+ T cells with a phenotype distinct from that of naive PA T cells.
    Kwok WW; Yang J; James E; Bui J; Huston L; Wiesen AR; Roti M
    Infect Immun; 2008 Oct; 76(10):4538-45. PubMed ID: 18678674
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen-specific CD4+ T cells recognize epitopes of protective antigen following vaccination with an anthrax vaccine.
    Laughlin EM; Miller JD; James E; Fillos D; Ibegbu CC; Mittler RS; Akondy R; Kwok W; Ahmed R; Nepom G
    Infect Immun; 2007 Apr; 75(4):1852-60. PubMed ID: 17283103
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
    Quinn CP; Sabourin CL; Niemuth NA; Li H; Semenova VA; Rudge TL; Mayfield HJ; Schiffer J; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Brys AM; Hunt RE; Levesque D; Estep JE; Barnewall RE; Robinson DM; Plikaytis BD; Marano N;
    Clin Vaccine Immunol; 2012 Nov; 19(11):1730-45. PubMed ID: 22933399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequency of epitope-specific naive CD4(+) T cells correlates with immunodominance in the human memory repertoire.
    Kwok WW; Tan V; Gillette L; Littell CT; Soltis MA; LaFond RB; Yang J; James EA; DeLong JH
    J Immunol; 2012 Mar; 188(6):2537-44. PubMed ID: 22327072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bivalent Protein r-PAbxpB Comprising PA Domain IV and Exosporium Protein BxpB Confers Protection Against
    Majumder S; Das S; Somani VK; Makam SS; Kingston JJ; Bhatnagar R
    Front Immunol; 2019; 10():498. PubMed ID: 30941133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen.
    Boyaka PN; Tafaro A; Fischer R; Leppla SH; Fujihashi K; McGhee JR
    J Immunol; 2003 Jun; 170(11):5636-43. PubMed ID: 12759444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural exposure to cutaneous anthrax gives long-lasting T cell immunity encompassing infection-specific epitopes.
    Ingram RJ; Metan G; Maillere B; Doganay M; Ozkul Y; Kim LU; Baillie L; Dyson H; Williamson ED; Chu KK; Ascough S; Moore S; Huwar TB; Robinson JH; Sriskandan S; Altmann DM
    J Immunol; 2010 Apr; 184(7):3814-21. PubMed ID: 20208010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sublingual targeting of STING with 3'3'-cGAMP promotes systemic and mucosal immunity against anthrax toxins.
    Martin TL; Jee J; Kim E; Steiner HE; Cormet-Boyaka E; Boyaka PN
    Vaccine; 2017 Apr; 35(18):2511-2519. PubMed ID: 28343781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a novel multiepitope chimeric vaccine against anthrax.
    Aggarwal S; Somani VK; Gupta S; Garg R; Bhatnagar R
    Med Microbiol Immunol; 2019 Apr; 208(2):185-195. PubMed ID: 30671633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Host immunity to Bacillus anthracis lethal factor and other immunogens: implications for vaccine design.
    Altmann DM
    Expert Rev Vaccines; 2015 Mar; 14(3):429-34. PubMed ID: 25400140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anthrax lethal toxin and the induction of CD4 T cell immunity.
    Ascough S; Ingram RJ; Altmann DM
    Toxins (Basel); 2012 Oct; 4(10):878-99. PubMed ID: 23162703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen.
    Oscherwitz J; Quinn CP; Cease KB
    Vaccine; 2015 May; 33(20):2342-6. PubMed ID: 25820066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and Characterization of Human Monoclonal Antibodies Targeting Anthrax Protective Antigen following Vaccination with a Recombinant Protective Antigen Vaccine.
    Chi X; Li J; Liu W; Wang X; Yin K; Liu J; Zai X; Li L; Song X; Zhang J; Zhang X; Yin Y; Fu L; Xu J; Yu C; Chen W
    Clin Vaccine Immunol; 2015 May; 22(5):553-60. PubMed ID: 25787135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasmid-based vaccination with candidate anthrax vaccine antigens induces durable type 1 and type 2 T-helper immune responses.
    Zhang Y; Qiu J; Zhou Y; Farhangfar F; Hester J; Lin AY; Decker WK
    Vaccine; 2008 Jan; 26(5):614-22. PubMed ID: 18166249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antibody responses to Bacillus anthracis protective antigen domain IV by use of calreticulin as a chimeric molecular adjuvant.
    Park YS; Lee JH; Hung CF; Wu TC; Kim TW
    Infect Immun; 2008 May; 76(5):1952-9. PubMed ID: 18285494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores.
    Welkos S; Little S; Friedlander A; Fritz D; Fellows P
    Microbiology (Reading); 2001 Jun; 147(Pt 6):1677-1685. PubMed ID: 11390699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Humoral and Cell-Mediated Immune Responses to Alternate Booster Schedules of Anthrax Vaccine Adsorbed in Humans.
    Quinn CP; Sabourin CL; Schiffer JM; Niemuth NA; Semenova VA; Li H; Rudge TL; Brys AM; Mittler RS; Ibegbu CC; Wrammert J; Ahmed R; Parker SD; Babcock J; Keitel W; Poland GA; Keyserling HL; El Sahly H; Jacobson RM; Marano N; Plikaytis BD; Wright JG
    Clin Vaccine Immunol; 2016 Apr; 23(4):326-38. PubMed ID: 26865594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody and functional mapping of Bacillus anthracis protective antigen-The first step toward a rationally designed anthrax vaccine.
    McComb RC; Martchenko M
    Vaccine; 2016 Jan; 34(1):13-9. PubMed ID: 26611201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anthrax lethal factor as an immune target in humans and transgenic mice and the impact of HLA polymorphism on CD4+ T cell immunity.
    Ascough S; Ingram RJ; Chu KK; Reynolds CJ; Musson JA; Doganay M; Metan G; Ozkul Y; Baillie L; Sriskandan S; Moore SJ; Gallagher TB; Dyson H; Williamson ED; Robinson JH; Maillere B; Boyton RJ; Altmann DM
    PLoS Pathog; 2014 May; 10(5):e1004085. PubMed ID: 24788397
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased long-term immunity to Bacillus anthracis protective antigen in mice immunized with a CIA06B-adjuvanted anthrax vaccine.
    Wui SR; Han JE; Kim YH; Rhie GE; Lee NG
    Arch Pharm Res; 2013 Apr; 36(4):464-71. PubMed ID: 23440578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.